Edwards Lifesciences (EW) Stock Overview
Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EW Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.88 |
| 52 Week High | US$89.60 |
| 52 Week Low | US$72.30 |
| Beta | 0.87 |
| 1 Month Change | 0.12% |
| 3 Month Change | 5.13% |
| 1 Year Change | 14.02% |
| 3 Year Change | -4.03% |
| 5 Year Change | -16.28% |
| Change since IPO | 6,145.82% |
Recent News & Updates
Narrative Update • Jun 17
EW: CMS TAVR Expansion And New CFO Will Shape Balanced Outlook
Analysts have modestly fine-tuned their Edwards Lifesciences valuation framework, keeping fair value essentially unchanged at about $96.92. They made modest adjustments to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E following the recent series of upward and downward price target revisions tied to the proposed TAVR coverage changes from CMS.Analysis Article • Jun 16
Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story
Edwards Lifesciences (EW) stock has drawn fresh attention as investors review its recent performance and financial profile, including a last close of $86.28 and full year revenue of $6,303.5 million. See our latest analysis for Edwards Lifesciences. Over the past year, Edwards Lifesciences has paired a 15.32% total shareholder return with steady short term momentum, including a 6.02% 1 month share price return and a 2.39% 3 month share price return. This performance suggests gradually...Narrative Update • Jun 03
EW: TAVR Share Gains And New CFO Will Shape Balanced 2026 Outlook
Edwards Lifesciences received a modest price target increase to $104, up $7, as analysts cited incremental TAVR share gains, steady double-digit top-line expectations, and room for margin improvement as key supports for the updated valuation assumptions. Analyst Commentary Recent research on Edwards Lifesciences reflects a mix of optimism about growth execution and some pushback on how much of that outlook is already reflected in the stock price.Recent updates
Narrative Update • Jun 17
EW: CMS TAVR Expansion And New CFO Will Shape Balanced Outlook
Analysts have modestly fine-tuned their Edwards Lifesciences valuation framework, keeping fair value essentially unchanged at about $96.92. They made modest adjustments to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E following the recent series of upward and downward price target revisions tied to the proposed TAVR coverage changes from CMS.Analysis Article • Jun 16
Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story
Edwards Lifesciences (EW) stock has drawn fresh attention as investors review its recent performance and financial profile, including a last close of $86.28 and full year revenue of $6,303.5 million. See our latest analysis for Edwards Lifesciences. Over the past year, Edwards Lifesciences has paired a 15.32% total shareholder return with steady short term momentum, including a 6.02% 1 month share price return and a 2.39% 3 month share price return. This performance suggests gradually...Narrative Update • Jun 03
EW: TAVR Share Gains And New CFO Will Shape Balanced 2026 Outlook
Edwards Lifesciences received a modest price target increase to $104, up $7, as analysts cited incremental TAVR share gains, steady double-digit top-line expectations, and room for margin improvement as key supports for the updated valuation assumptions. Analyst Commentary Recent research on Edwards Lifesciences reflects a mix of optimism about growth execution and some pushback on how much of that outlook is already reflected in the stock price.Narrative Update • May 12
EW: 2026 LAA Closure Entry Will Drive Future Upside Repricing
Edwards Lifesciences' updated analyst price target edges higher by about $0.20, reflecting analysts' slightly stronger assumptions on long term revenue growth, profit margins, and a modestly lower discount rate, even as recent Street research showed a mix of price target raises and cuts across firms such as Barclays, Truist, Evercore ISI, BTIG, Baird, BofA, Mizuho, UBS, Goldman Sachs, and Piper Sandler. Analyst Commentary Recent research shows a split view on Edwards Lifesciences, with some firms lifting price targets and others trimming them or turning more cautious.Narrative Update • Apr 28
EW: 2026 LAA Closure Opportunity Will Support Future Upside Repricing
Analysts have inched their blended price target for Edwards Lifesciences higher by roughly $0.04 to about $96.96. This reflects updated assumptions around slightly lower modeled revenue growth, a modestly higher discount rate, a firmer profit margin outlook, and a somewhat lower future P/E multiple after recent mixed target moves across the Street.Narrative Update • Apr 10
EW: 2026 LAA Closure Expansion Will Support Upside Repricing
Analysts have nudged their fair value target for Edwards Lifesciences slightly lower to about $96.93, reflecting updated assumptions on discount rates, revenue growth, profit margins, and future P/E following a mix of recent price target cuts and raises across the Street. Analyst Commentary Recent research takes on Edwards Lifesciences point to a mixed but generally engaged stance from the Street, with both upgrades and target changes feeding into the updated fair value view.Narrative Update • Mar 27
EW: 2026 TAVR Indication Expansion And LAA Closure Plans Will Drive Upside
Analysts have made a modest upward adjustment to Edwards Lifesciences' intrinsic value estimate, with the fair value moving to $97.12. This is supported by research that highlights the company's expanding left atrial appendage closure offerings, its updated 2026 outlook after the canceled JenaValve deal, and a slightly higher assumed future P/E of about 33.8x.Narrative Update • Mar 12
EW: 2026 TAVR Expansion And New LAA Closure Will Drive Upside
Our view on Edwards Lifesciences now reflects a modestly higher blended Street price target. Analysts cite updated 2026 outlooks, the canceled JenaValve deal, and expectations around TAVR indication expansion and new left atrial appendage closure products as key drivers behind their revised $90 to $108 target range.Narrative Update • Feb 25
EW: 2026 TAVR Indication Expansion And Pipeline Progress Will Drive Upside
We are trimming our Edwards Lifesciences fair value estimate by about $0.64 per share to $96.46 as analysts balance a tighter future P/E assumption with slightly stronger margin and growth expectations, supported in part by recent research highlighting the company's pipeline progress and competitive positioning. Analyst Commentary Recent Street research around Edwards Lifesciences shows a mix of optimism on long term growth drivers and caution on competitive and execution risks, which feeds directly into how analysts are framing valuation today.Narrative Update • Feb 09
EW: TAVR Durability And 2026 Outlook Will Shape Upside Potential
Analysts made a marginal upward adjustment to their fair value estimate for Edwards Lifesciences to about US$97.11, reflecting a series of recent price target tweaks that balance more optimistic 2026 outlooks and model updates following the canceled JenaValve acquisition, along with at least one modest target reduction. Analyst Commentary Recent research has focused on how Edwards Lifesciences' updated 2026 outlook and the canceled JenaValve deal feed into valuation, growth expectations, and execution risk.Narrative Update • Jan 26
EW: TAVR Durability And 2026 Outlook Will Drive Renewed Upside
Analysts have nudged their fair value target for Edwards Lifesciences slightly higher to about $97 per share, reflecting modest adjustments to growth, margin, and P/E assumptions after a recent series of price target increases across Wall Street. Analyst Commentary Recent Street research around Edwards Lifesciences has tilted more positive, with several firms lifting price targets and a few moving up their ratings after company updates, product data releases, and the termination of the JenaValve acquisition.Narrative Update • Jan 11
EW: Long-Term TAVR Durability Will Support Renewed Upside Into 2026
Our fair value estimate for Edwards Lifesciences edges up to about $96 per share, reflecting slightly higher analyst price targets. These targets are grounded in expectations for steady organic growth in TAVR, confidence in Sapien durability from long term PARTNER 3 data, and growing interest in Evoque driven opportunities into 2026.Analysis Article • Jan 04
Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Seeking Alpha • Dec 29
The Edwards Lifesciences Dilemma Persists: Strong Growth Potential, High Price
Summary Edwards Lifesciences offers robust 10%+ revenue growth potential, but current valuation remains rich and could limit near-term upside. EW's TAVR business has reaccelerated from early in 2025, supported by new clinical data and guideline changes, and TMTT could double revenue share by 2030. Competitive risks from MDT, BSX, and ABT persist, but EW's pipeline and recent FDA approvals underpin credible long-term growth targets. I see margin expansion and free cash flow leverage ahead, yet I would await a pullback before considering new positions at these levels. Read the full article on Seeking AlphaNarrative Update • Dec 27
EW: Long-Term TAVR Durability And Coverage Shifts Will Support Balanced Future Upside
Analysts have nudged their average price target on Edwards Lifesciences modestly higher, with fair value estimates rising to about $95.80 from roughly $95.37. They cite strong Q3 outperformance, accelerating transcatheter aortic valve replacement growth, and increased confidence in long term TAVR durability and related coverage catalysts.Narrative Update • Dec 11
EW: Long-Term TAVR Durability Will Drive Future Low-Risk Expansion
Analysts have modestly raised their fair value estimate for Edwards Lifesciences to approximately $95 from about $94, reflecting a blend of slightly lower perceived risk, resilient high-20s profit margin expectations, and stronger confidence in long term transcatheter aortic valve replacement growth following robust Q3 results and favorable recent clinical and coverage catalysts. Analyst Commentary Street research sentiment around Edwards Lifesciences has turned more constructive, with multiple firms lifting ratings and price targets following strong Q3 execution, favorable TAVR data presentations, and improving confidence in long term growth durability.Narrative Update • Nov 27
EW: Durable Outcomes And Low-Risk Data Will Guide Forward Opportunity And Uncertainty
Edwards Lifesciences' average analyst price target has moved higher. Increases range from $4 to $10, as analysts cite a strong Q3, upbeat guidance, and growing confidence in key clinical results as drivers for their upward revisions.Narrative Update • Nov 12
EW: Future Progress Will Hinge On Durable Outcomes And Market Expansion
The analyst price target for Edwards Lifesciences has increased from approximately $88.83 to $93.94. Analysts point to strong quarterly results and sustained momentum in transcatheter aortic valve replacements as key drivers of the upward revision.Narrative Update • Oct 29
Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead
Edwards Lifesciences' analyst price target has risen from $87.73 to $88.83. Analysts cite improved transcatheter aortic valve replacement data and heightened confidence in the company's long-term outlook following positive clinical results.Analysis Article • Sep 20
Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching
Today we're going to take a look at the well-established Edwards Lifesciences Corporation ( NYSE:EW ). The company's...Analysis Article • Sep 05
Here's What's Concerning About Edwards Lifesciences' (NYSE:EW) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Analysis Article • Jul 16
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$79.45 With...Seeking Alpha • Mar 23
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead
Summary Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic. Technically, EW shares are rangebound with resistance at $76 and support between $67-$68, indicating potential sideways trading action. Read the full article on Seeking AlphaSeeking Alpha • Jan 05
Edward Lifesciences: A Closer Look At Growth And Valuation
Summary Edward Lifesciences remains a "Hold" as it trades close to its intrinsic value, despite improved fundamentals and solid third-quarter results. Valuation multiples are misleading; P/E ratio is extremely low, but P/FCF ratio is high due to non-representative earnings and free cash flow. The sale of the "Critical Care" business boosted EPS, but sustainable growth stems from core segments like TAVR and TMTT, with long-term revenue growth expected at 10%. With a strong balance sheet and potential for share buybacks, Edward Lifesciences needs 14% annual FCF growth to be fairly valued; I prefer waiting for a lower price. Read the full article on Seeking AlphaShareholder Returns
| EW | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.5% | -2.7% | -1.8% |
| 1Y | 14.0% | -22.1% | 23.3% |
Return vs Industry: EW exceeded the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: EW underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| EW volatility | |
|---|---|
| EW Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EW's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 16,000 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EW fundamental statistics | |
|---|---|
| Market cap | US$50.30b |
| Earnings (TTM) | US$1.08b |
| Revenue (TTM) | US$6.30b |
46.0x
P/E Ratio7.8x
P/S RatioIs EW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EW income statement (TTM) | |
|---|---|
| Revenue | US$6.30b |
| Cost of Revenue | US$1.40b |
| Gross Profit | US$4.91b |
| Other Expenses | US$3.83b |
| Earnings | US$1.08b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 77.87% |
| Net Profit Margin | 17.06% |
| Debt/Equity Ratio | 5.8% |
How did EW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/22 15:45 |
| End of Day Share Price | 2026/06/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edwards Lifesciences Corporation is covered by 51 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |